GlassScriptPhysician profile
Wael Alabdulkarim
NPI 1154383313
$11,244.36
in general payments reported to CMS, 2019-2025
44 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $1,766 · 2021: $1,972 · 2022: $1,613 · 2023: $1,323 · 2024: $1,844 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,244.13 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $2,128.36 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Sk Life Science, INC. | $761.99 | 2020-2024 | Xcopri |
| Lundbeck LLC | $539.02 | 2020-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $492.24 | 2019-2021 | |
| Amgen INC. | $396.99 | 2019-2021 | |
| Pfizer INC. | $384.48 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $381.77 | 2020-2025 | Ingrezza |
| Allergan, INC. | $344.72 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $301.45 | 2019-2022 | |
| Biogen, INC. | $295.38 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $287.73 | 2019-2021 | |
| Argenx US, INC. | $287.26 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $250.20 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $233.56 | 2019-2025 | Rytary, Crexont |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Alabdulkarim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.